Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2009 - 2017)

Regeneron Pharmaceuticals' Long-Term Debt Repayments history runs 9 years deep, the most recent figure standing at -$25000.0 for Q4 2017.

• In Q4 2017, Long-Term Debt Repayments fell 110.0% year-over-year to -$25000.0; the TTM figure through Sep 2018 stood at -$25000.0 (down 100.12% YoY), while the FY2017 annual figure was $19.9 million, up 54.26% from the prior year.
• Long-Term Debt Repayments was -$25000.0 for Q4 2017 at Regeneron Pharmaceuticals, down from $7.1 million in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $221.4 million in Q4 2014 to a low of -$3.6 million in Q4 2013.
• Historically, Long-Term Debt Repayments has averaged $17.4 million across 5 years, with a median of $808500.0 in 2013.
• The sharpest annual moves came in 2013 and 2014: Long-Term Debt Repayments tumbled 706.15% in 2013, then surged 6168.76% in 2014.
• A 5-year view of Long-Term Debt Repayments shows it stood at -$3.6 million in 2013, then soared by 6168.76% to $221.4 million in 2014, then plunged by 99.56% to $968000.0 in 2015, then slumped by 74.17% to $250000.0 in 2016, then plunged by 110.0% to -$25000.0 in 2017.
• The last three Long-Term Debt Repayments figures came in at -$25000.0 (Q4 2017), $7.1 million (Q2 2017), and $12.9 million (Q1 2017), per Business Quant data.